Loading
Led DESTINY-Breast01 and DESTINY-Breast04, the trials that created the HER2-low category and opened T-DXd to most breast cancers.
Shanu Modi was lead investigator of DESTINY-Breast01, the study that won trastuzumab deruxtecan its first approval, and of DESTINY-Breast04, which showed the ADC halves the risk of progression in HER2-low disease previously treated as HER2-negative. That trial redefined breast cancer classification and extended ADC therapy to roughly half of all patients. She continues to lead ADC trials at MSKCC.
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tags breast, adc.
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tags breast, adc.
Shares Memorial Sloan Kettering Cancer Center, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag breast.
Shares DESTINY-Breast04, Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC) and the tag breast.
Shares Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags breast, adc.
Shares Memorial Sloan Kettering Cancer Center, Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC).
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
Shares DESTINY-Breast04, Trastuzumab deruxtecan, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.